Selenocysteine, the 21st genetically encoded amino acid, is the major form of the antioxidant trace element selenium in the human body. In eukaryotes and archaea its synthesis proceeds through a phosphorylated intermediate in a tRNAdependent fashion. The final step of selenocysteine formation is catalyzed by O-phosphoseryl-tRNA:selenocysteinyltRNA synthase (SepSecS) that converts phosphoseryltRNA Sec to selenocysteinyl-tRNA Sec . The human SepSecS protein is also known as soluble liver antigen/liver pancreas (SLA/LP), which represents one of the antigens of autoimmune hepatitis. Here we review the discovery of human SepSecS and the current understanding of the immunogenicity of SLA/LP in autoimmune hepatitis.
Introduction
Selenium is an essential antioxidant micronutrient for humans. The 21st genetically encoded amino acid, selenocysteine (Sec), is the principal metabolite of selenium in the human body and the means for exerting its various health benefits (Rayman, 2000) . Although chemically similar to cysteine (Cys), Sec is significantly more nucleophilic at physiological pH. The lower pK a of the selenol group (approx. 5.2) ensures that the ionized selenolate form is dominant within the cell. This is in stark contrast to the predominantly reduced thiol group (pK a 8.5) in Cys (Ambrogelly et al., 2007) . Similarly to the rest of the 20 canonical amino acids Sec is delivered to the ribosome for protein synthesis by its cognate transfer RNA (tRNA) molecule, tRNA Sec .
Knockout of tRNA
Sec in the mouse is embryonic lethal, which underscores the importance of Sec-containing proteins (or selenoproteins) in mammalian development (Bösl et al., 1997) . Mutations and polymorphisms in several of the currently known 25 human selenoproteins have been implicated in cancer and diseases of the muscular, nervous, immune and endocrine systems (reviewed in Bellinger et al., 2009 ). This is not surprising because most selenoenzymes (i.e., thioredoxin reductase, glutathione peroxidase, thioredoxin/glutathione reductase and methionine sulfoxide reductase) safeguard the cell from the detrimental effects of reactive oxygen species and regenerate important antioxidants such as vitamin C, vitamin E and coenzyme Q (Lu and Holmgren, 2009) . Sec is also the catalytic residue in iodothyronine deiodinases, the enzymes that enable circulating thyroid hormone to exert its pro-metabolic actions in peripheral tissues. The erroneous replacement of the active site Sec with the chemically similar serine (Ser) or Cys diminishes the activity of several selenoenzymes (Zhong and Holmgren, 2000; Kuiper et al., 2003) .
Selenocysteine, an eccentric amino acid
Sec is unique among amino acids in two respects. First, the codon that specifies Sec is one of the stop codons. In the late 1980s and early 1990s, Sec was established as the 21st genetically encoded amino acid specified by UGA that normally serves as a stop codon. Apart from its most common function to signal translational termination and its reassignment to Cys in Euplotes (Meyer et al., 1991) an in-frame UGA codon within the coding region of certain proteins also codes for selenocysteine in organisms from all three domains of life (reviewed in Ambrogelly et al., 2007 ). An elegant recoding mechanism allows the translation machinery to accurately discriminate between a Sec UGA and a Stop UGA codon. The presence of a stem-loop structure known as the selenocysteine insertion sequence (SECIS) element in the mRNA of selenoproteins signals the insertion of Sec to the translation apparatus. SECIS is present right after the UGA to be recoded in bacterial selenoprotein mRNAs, whereas it is mostly in the 39 UTR in eukaryotic and archaeal mRNAs, which allows for the insertion of multiple Sec residues in a single eukaryotic polypeptide (Zinoni et al., 1990; Berry et al., 1991; Wilting et al., 1997) . (Biou et al., 1994) , the archaeal PSTK (Araiso et al., 2009) , the human SepSecS-tRNA Sec complex , the human tRNA Sec (Itoh et al., 2009) , the archaeal SelB (Leibundgut et al., 2005) and that of the bacterial 70S ribosome in complex with EF-Tu (Schmeing et al., 2009) were used for modeling. Except for the SepSecS-tRNA Sec complex, all other complexes are proposed models and not true structures.
Secondly, Sec is the universal exception to Crick's paradigm that there should be one aminoacyl-tRNA synthetase (AARS) for each genetically encoded amino acid. AARSs are the enzymes that 'read' the genetic code by selecting the right amino acid and pairing it with its cognate tRNA. A prerequisite for this process is the presence of a cellular pool of free amino acids synthesized before this step. Indeed, biochemical experimental efforts of the last century have identified biosynthetic pathways for all 20 canonical amino acids. Sec is the only exception; there is no biosynthetic pathway for free Sec formation within the cell and a selenocysteinyltRNA synthetase does not exist. Instead, Sec synthesis occurs on its cognate tRNA in a route that is based on misacylation by seryl-tRNA synthetase (SerRS) and subsequent tRNAdependent amino acid transformation.
The route to Sec synthesis
Sec synthesis is interwoven with Sec-tRNA formation in all Sec-encoding bacterial, archaeal and eukaryal organisms. It begins with the misacylation of tRNA Sec with Ser by SerRS ( Figure 1 (Carlson et al., 2004) . Moreover, in contrast to most AARSs that bind their cognate tRNAs with micromolar affinities, PSTK binds both unacylated and serylated tRNA Sec with nanomolar affinity (Diamond et al., 1993) .
While the discovery of PSTK lent credence to the old finding of Sep-tRNA Sec in mammalian cell extracts (Mäen-pää and Bernfield, 1970) , the concomitant discovery of SeptRNA:Cys-tRNA synthase (SepCysS) in some methanogenic archaea paved the way for the elucidation of the route to Sec synthesis from Sep-tRNA in archaea and eukarya (Sauerwald et al., 2005 (Yuan et al., 2006; Abe et al., 2007; Xu et al., 2007) .
Human SepSecS or SLA/LP
The most promising candidate to exhibit such an activity was the human protein Soluble Liver Antigen/Liver Pancreas (SLA/LP). This protein was first identified in the early 1990s as it co-precipitated with tRNA Sec when mammalian cell extracts were treated with serum from patients with autoimmune hepatitis (Gelpi et al., 1992) . Through a computational approach SLA/LP was classified as a PLP-dependent serine hydroxymethyltransferase (Kernebeck et al., 2001) and its archaeal orthologs were only found in known Seccontaining archaea (Yuan et al., 2006) . Interestingly, other known tRNA-dependent enzymes that carry out Ser or Sep conversions also require PLP for activity Sauerwald et al., 2005) . In vivo complementation assays in a heterologous system and in vitro activity assays established the human SLA/LP and its archaeal orthologs as the Sep-tRNA:Sec-tRNA synthase (SepSecS). SepSecS performs the ultimate step in the route to Sec synthesis, the conversion of Sep-tRNA Sec to Sec-tRNA Sec (Yuan et al., 2006; Abe et al., 2007; Xu et al., 2007; see Figure 1 ). However, earlier RNA interference results in mammalian cells could not exclude the existence of an alternative SepSecSindependent pathway of Sec-tRNA Sec (Xu et al., 2005) . Genetic knockouts and in vivo selenoprotein analysis in the parasitic protozoon Trypanosoma brucei showed that the PSTK/SepSecS sequence is the sole route to Sec in T. brucei, and thus possibly in all eukaryotes (Aeby et al., 2009) .
Crystal structures of the archaeal (Araiso et al., 2008 ) and murine apo-SepSecS (Ganichkin et al., 2008) and the most recent of the human SepSecS-tRNA Sec complex ) revealed the basis of substrate specificity and the catalytic mechanism of SepSecS. Its homotetrameric structure is distinct from its closest homologue, the dimeric SepCysS, and places SepSecS in its own branch in the family of fold type I PLP-dependent enzymes that stems from the last universal common ancestor (Araiso et al., 2008) . Biochemical assays and molecular genetics established a reaction mechanism that proceeds through an external aldimine formed between the bound PLP cofactor and the incoming Sep that is attached to tRNA Sec Comprised of 90 nucleotides, human tRNA Sec is among the largest eukaryotic tRNAs, the structure of which was recently determined (Itoh et al., 2009; Palioura et al., 2009) . Its acceptor-TCC 'helix' contains an additional base pair resulting in a 9/4 fold, in contrast to the 7/5 fold adopted by all known canonical tRNAs (Sturchler et al., 1993) . Except for tRNA Sec , all tRNAs are transferred to the ribosome bound to either EF-Tu in bacteria or eEF1A in eukaryotes. The atypical 9/4 fold of tRNA Sec accounts for the evolution of a specialized elongation factor, known as SelB in bacteria (Forchhammer et al., 1989) and EFSec in eukaryotes (Fagegaltier et al., 2000; Tujebajeva et al., 2000) , which binds only Sec-tRNA Sec and not other aminoacyl-tRNAs. Both the variable and D arms of tRNA Sec are longer than the corresponding elements in canonical tRNAs Itoh et al., 2009) , whereas the eighth position in tRNA Sec is occupied by adenine instead of the highly conserved uridine which is found in all canonical tRNAs. In a striking contrast to U8, the base of A8 does not form any tertiary interactions with the D-and TCC arms leaving a hole in the core of the tRNA molecule (Yuan et al., 2010) . All these features result in a distinct three-dimensional structure of tRNA Sec , which is likely to be recognized by all Sec-specific enzymes.
Whereas SerRS recognizes common structural features of tRNA Ser and tRNA Sec , it is thought that PSTK, SepSecS and EFSec recognize the distinct structural elements of tRNA Sec instead (Yuan et al., 2010) . The human SepSecS-tRNA Sec complex structure revealed that SepSecS does exactly that. It binds the longer acceptor-TCC 'helix', the long variable arm, the 59 phosphate and the acceptor-TCC-variable elbow. Practically, SepSecS measures the length of the acceptor-TCC 'helix' as the distance between the variable arm and the acceptor tip of tRNA Sec . Modeling of canonical tRNAs onto the human SepSecS showed that the length of their acceptor-TCC 'helix' is too short to reach the active site of the enzyme. Even if productive interaction between the tip of the acceptor arm and the enzyme were forced to form, multiple steric clashes would prevent binding of the canonical tRNA to SepSecS ).
SLA/LP in autoimmune hepatitis
Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease associated with autoantibodies and liver-infiltrating lymphocytes (Krawitt, 2006; Bogdanos et al., 2009 ). The The helix a14 residues interact with the discriminator base G73: Arg398 forms hydrogen bonds with the Hoogsteen face of G73, whereas Thr397 stabilizes this interaction. The C-terminal helix a15 interacts with the tRNA backbone and with the 59 phosphate. Arg453 and Arg456 are within hydrogen bonding distance from the 59 phosphate, whereas Lys463 interacts with the non-bridging oxygens of C69 and G70. pathogenesis of AIH is not understood, but it is assumed that the disease is driven by an inappropriate immune response against self antigens. Indeed, the majority of the patients present with autoantibodies that most commonly recognize nuclear antigens (ANA), filamentous actin (SMA), perinuclear antigen of neutrophils (atypical p-ANCA), the SepSecS molecule (SLA/LP), or cytochrome P450 2D6 (LKM-1) (Krawitt, 2006) . SLA/LP autoantibodies are present in approximately 20% of the patients (Manns et al., 1987; Wies et al., 2000; Baeres et al., 2002) In contrast to all other autoantibodies detectable in immune-mediated liver diseases, SLA/LP autoantibodies are highly specific for autoimmune hepatitis (Baeres et al., 2002) . SLA/LP autoantibodies seem to react specifically with an immunodominant region of the SLA/LP molecule located near the carboxy-terminus between amino acids 450 and 490 (FINRLDRCLKAVR-KERSKESDDNYDKTEDVDIEEMALKLDN), as identified by analysis of carboxy-terminally truncated proteins (Wies et al., 2000) . By analyzing a set of overlapping linear peptides covering this region, the dominant epitope recognized by SLA/LP autoantibodies could be confirmed and further restricted to a linear epitope sequence of 30 amino acids (residues 459-490: KAVRKERSKESDDNYDKTEDVDIE-EMALKLDN) . Interestingly, two immunodominant CD4 T cell epitopes have been identified, of which one is situated within the immunodominant region recognized by autoantibodies (residues 452-465: NRLDR-CLKAVRKER) .
In the structure of the human SepSecS-tRNA Sec binary complex the first 14 residues of the antigenic region (residues 450-463: FIKRLDRCLKAVRK) form the C-terminal helix a15 . Interestingly, helix a15 is spatially located near the entrance to the active-site cleft and it is proximal to helix a14 (Figure 2A ). Both a14 and a15 interact with distinct parts of the acceptor arm (Figure 2A) . The side chains of Thr397 and Arg398 from helix a14 interact with the discriminator base G73 and, thus, establish the identity of the bound tRNA molecule ( Figure 2B ). The importance of Thr397 and Arg398 for tRNA Sec binding has been confirmed by in vivo studies . By contrast, the residues Arg453, Arg456 and Lys463 in a15 form the 59-phosphate binding groove and they interact with the tRNA backbone atoms ( Figure 2B ). Since autoantibodies from patients with autoimmune hepatitis can precipitate the ribonucleoprotein SepSecS-tRNA Sec complex, we have proposed that such autoantibodies bind to an interface that lies between the a14 and a15 helices of SepSecS and the tip of the acceptor arm of tRNA Sec ( Figure 2B ). The remaining residues of the antigenic region (residues 463-501) form the extreme C-terminal tail of SepSecS and have been disordered in all crystal structures of the enzyme determined to date (Araiso et al., 2008; Ganichkin et al., 2008; Palioura et al., 2009 ). This more flexible region of the enzyme would be more amenable to the proteolytic cleavage steps required for presentation to the immune system.
The remarkable uniformity in epitope recognition among the patients suggests that autoimmunity to SLA/LP is antigen-driven and induced by a common mechanism . Most probably, autoimmunity to SepSecS is driven by the human SepSecS antigen itself and not by molecular mimicry (Wang et al., 2006) . Thus, it is likely that SLA/LP autoimmunity is related to the pathogenesis of autoimmune hepatitis, at least in the subgroup of patients who display anti-SLA/LP reactivity. However, it is currently not clear how the biosynthesis of selenocysteine could be related to autoimmune hepatitis. Selenoproteins are synthesized in various organs, but nutritional selenium is mainly metabolized in the liver, from where selenium is distributed to other organs in the form of selenoprotein P (Gromer et al., 2005) . One could thus speculate that nutritional selenium compounds or their metabolites or, alternatively, selenium deficiency might alter hepatic SepSecS in such ways that it becomes an immunogenic neoantigen. Such alterations could include dysfunction of the SepSecS enzyme, aberrant subcellular localization of SepSecS molecules in hepatocytes, or the formation of immunogenic molecular complexes of SepSecS with other proteins or non-protein molecules.
However, it is conceivable that modifications of SepSecS molecules by metabolites in the liver may initiate an immune response to SepSecS. A similar scenario has been suggested to initiate autoimmunity to the pyruvate dehydrogenase complex in primary biliary cirrhosis, which seems to be related to lipoic acid and neoantigenic xenobiotic lipoic acid analogs (Bruggraber et al., 2003; Walden et al., 2008) . Of note, the catalytic domain of pyruvate dehydrogenase seems to carry a dominant target epitope of antimitochondrial antibodies in primary biliary cirrhosis patients (Braun et al., 2010) . Moreover, such antibodies to pyruvate dehydrogenase have been reported to inhibit its enzymatic activity (Van de Water et al., 1988; Teoh et al., 1994) . Given that autoantibodies to the SepSecS molecule also seem to target the catalytic domain, it is thus possible that SLA/LP autoantibodies could inhibit the enzymatic function of SepSecS and thereby contribute to the pathogenesis of autoimmune hepatitis.
